Mark Shutov said that the center selected the three most promising vaccines from the six vaccines developed for preparation for clinical trials at the end of June. One of the vaccines, which is based on peptide antigens, not only differs in functional origin, but also has different immunization methods and protocols. It is not usually administered by intramuscular injection, but by intranasal instillation. The technical route for the development of this vaccine was well verified when the Ebola virus vaccine was developed in 2018.
The animal test results of the above three vaccines show that after injection of the vaccine, the animals did not experience an increase in body temperature and no adverse reactions were observed. This shows that the animals show good tolerance to the vaccine. Mark Shutov said that in order to monitor possible changes in the animal’s lungs, the researchers also used X-ray machines to confirm.
The Russian National Vector Center for Virology and Biotechnology in Siberia is the leader in the development of new coronavirus vaccines. The center uses recombinant protein vaccines and synthetic vaccines to devote efforts to vaccine research and development on six technical routes. Among them, influenza, measles and vesicular stomatitis viruses have been used in the recombinant protein vaccine and synthetic vaccine technical routes. Animal experiments were carried out on April 13.
Previously, the National Research Center for Epidemiology and Microbiology of the Russian Ministry of Health and the Russian Ministry of Defense jointly developed an adenoviral vector vaccine and The staff who developed the new coronavirus vaccine conducted vaccination tests. The center director Günzburg said the test showed that the vaccine performed well and had produced protective antibodies. But he pointed out that this should not be regarded as a test of the vaccine, this is for self-protection to continue to work.
WHO has included the research results of 9 new coronavirus vaccines developed by Russia in the candidate list, 6 of which are produced by the “Vector” National Science of Virology and Biotechnology Developed by the center, 2 models are from the Russian biomedical company Biocad and 1 model is from the Saint Petersburg Vaccine and Serum Research Institute.
(Original title: Russia: Developed a new intranasal drip vaccine)